Gefitinib
First-generation EGFR tablet for mutated lung cancer.
- Starts working
- Depends on the cancer and regimen
- Half-life
- About 48 hours
- In use since
- —
- Pregnancy
- Usually avoided
Overview
Gefitinib blocks EGFR in lung cancer with EGFR mutations. It causes rash and diarrhoea, and acid-reducing medicines weaken its absorption.
Conditions it's used for
How it works
Blocks a growth signal in EGFR-mutated lung cancer.
Gefitinib belongs to the Tyrosine kinase inhibitors. How Tyrosine kinase inhibitors work: block a faulty 'on switch' protein that a cancer depends on.
Uses
- EGFR-mutated non-small-cell lung cancer
Available as: tablet.
Typical dose
- Adults
- Dosed by your cancer team according to the treatment protocol.
- Good to know
- Doses depend on body size, blood counts and the regimen.
Typical doses for orientation only. Your prescription, the pack leaflet and local guidance take priority.
Side effects
Common
Often mild and may settle with time
- Acne-like rash
- Diarrhoea
- Dry skin
- Nausea
- Tiredness
Serious — get medical help
Uncommon, but need prompt attention
- Lung inflammation
- Liver injury
- Bowel perforation
Warnings
- Take at the same time each day
Who should avoid it
- Pregnancy
- Severe liver impairment
Interactions
- Warfarin — INR rises
- PPIs and H2 blockers — lower absorption
- Rifampicin, phenytoin — lower levels
- Itraconazole — raised levels
Other medicines in the atlas that need care with Gefitinib, grouped by the reason:
Reduced effectModerateWith Carbamazepine, Efavirenz, Enzalutamide, Griseofulvin, Modafinil and 5 more
Enzyme induction lowers levels of this medicine, which may stop it working.
What's usually done: Monitor effect; dose changes or alternatives may be needed. The effect lasts weeks after stopping the inducer.
Raised drug levelsModerateWith Clarithromycin, Darunavir, Erythromycin, Itraconazole, Lopinavir-ritonavir and 2 more
Blocking CYP3A4 increases levels of this medicine, so side effects become more likely.
What's usually done: A dose reduction, alternative or extra monitoring may be needed.
Using it safely
- Alcohol
- Best to limit. Alcohol may add to liver strain.
- Food and drink
- With or without food.
- If you miss a dose
- Take when remembered; skip if within 12 hours of the next dose.
- Stopping it
- Only on advice of your cancer team.
- Driving
- Tiredness may affect driving.
- Tests and checks
- Liver tests; Rash; Breathing
- If too much is taken
- Seek medical advice.
- Storage
- Room temperature.
- Legal status
- United States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM)India: Schedule HAustralia: Prescription only (Schedule 4)
Pregnancy and breastfeeding
Pregnancy
Usually avoided
Avoid.
Breastfeeding
Usually avoided
Avoid.
Special groups
- Kidney disease
- Dose may need adjusting; your team will advise.
- Liver disease
- Dose may need adjusting; your team will advise.
- Older adults
- Older adults may be more sensitive to side effects.
Brand names
- United States
- Iressa
- United Kingdom
- Iressa
- India
- Iressa, Gefitinib (generic)
- Australia
- Iressa
Examples only; many generic versions exist. The same brand name can mean different products in different countries.
Common questions
Do I need a prescription for Gefitinib?
Yes — Gefitinib is prescription-only in most countries.
Can I take Gefitinib during pregnancy?
Usually avoided. Avoid. Always check with a doctor or midwife.
How quickly does Gefitinib work?
Depends on the cancer and regimen.
Related medicines
Erlotinib
EGFR tablet for lung cancers with EGFR mutations.
RxWHOTyrosine kinase inhibitorsOsimertinib
Targeted pill for EGFR-mutated lung cancer.
RxTyrosine kinase inhibitorsCarboplatin
Platinum chemotherapy with less nerve and kidney toxicity than cisplatin.
RxWHOPlatinum chemotherapyImatinib
Targeted pill that turned a deadly leukaemia into a manageable condition.
RxWHOTyrosine kinase inhibitorsSorafenib
Multi-kinase tablet for liver, kidney and thyroid cancers.
RxTyrosine kinase inhibitorsSunitinib
Multi-kinase capsule for kidney cancer and GIST.
RxWHOTyrosine kinase inhibitors
Sources and official information
- MedlinePlus (US National Library of Medicine)
- DailyMed — official US labels
- NHS medicines A–Z
- WHO ATC/DDD index — L01EB01
- WHO Model List of Essential Medicines
Entry last reviewed October 2026. Compiled from WHO, NHS, FDA/DailyMed, BNF and national formulary information. How we write entries.